Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.